Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA

Inclusion Criteria: * Adequate organ function as defined by laboratory values per protocol * Documented diagnosis of MDS by World Health Organization (WHO) criteria, further meeting the following criteria according to disease risk classification * Patients must be transfusion dependent, defined as requirement for transfusion of at least 3 units of Packed Red Blood cells (PRBCs) 16 weeks for a Hgb\<9.0g/dL or, in non-transfusion dependent patients (\<3 units of PRBCs transfused in the preceding 16 weeks), must have a baseline Hgb of \<9.0 g/dL at time of study enrollment * Eastern Cooperative Oncology Group (ECOG) Performance Status \</=2. * Women of child bearing potential must have negative urine or serum pregnancy test within 28 days prior to start of study drug. * Women of child bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence; tubal ligation, partner's vasectomy) prior to Cycle 1 Day 1 and for the duration of study participation. Exclusion Criteria: * Use of chemotherapeutic agents or experimental agents (agents that are not commercially available) for the treatment of MDS within 14 days of the first day of study drug treatment. * Previous treatment with a hypomethylating agent (such as azacitidine, decitabine or investigational hypomethylating agent). * Use of concurrent growth factors such as G-CSF, GM-CSF, or thrombopoietin mimetics during study except in cases of febrile neutropenia, where G-CSF can…